Investing.com -- Morgan Stanley analysts said Waters Corporation appears best positioned among life science diagnostic companies following China's finalized clinical laboratory service pricing framework, which was published a couple of weeks ago by the National Healthcare Security Administration.

The framework covers 662 main items, 114 add-ons, and seven extensions. It preserves the methodology-neutral structure proposed in March and retains differentiated treatment for advanced workflows including mass spectrometry. The guidelines introduce tiered discounts for multiplex panels and provide more detailed treatment of certain microbiology services. Provincial authorities will determine actual pricing in Chinese yuan and implementation timing.

Morgan Stanley said Waters benefits from its exposure to mass spectrometry and higher complexity microbiology workflows that retain differentiated treatment under the new framework. The company views the outcome as constructive for both clinical mass spectrometry and microbiology, according to the analysts.

Waters pointed to the preservation of specific surcharges for mass spectrometry and other higher complexity workflows, which should support clinical adoption by recognizing the clinical value of quantitative testing. In microbiology, the company noted more detailed treatment of blood culture, susceptibility testing, diagnostic analysis, and report generation.

For Danaher Corporation, the final framework aligns with management's prior assessment. The company previously indicated the March draft guidance was anticipated. Beckman Coulter's routine chemistry and immunoassay exposure faces standardized fees and pressure on hospital laboratory economics, while SCIEX mass spectrometry and MicroScan susceptibility testing should receive greater protection from premium add-ons.

Danaher identified approximately $320 million of exposed revenue in 2023, followed by headwinds of $50 million in 2024, $150 million in 2025, and $75 million to $100 million in 2026. The company is forecasted to generate over $26 billion in revenue this year.

Thermo Fisher Scientific has limited exposure given its portfolio composition. The recent divestiture of its microbiology business further reduces direct exposure.